A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications
- Registration Number
- NCT00644774
- Lead Sponsor
- Abbott
- Brief Summary
To compare the taste and smell acceptability of cefdinir (Omnicef) antibiotic suspension and azithromycin (Zithromax) antibiotic suspension following a single dose of each medication.
- Detailed Description
The Primary Purpose for the study is "Other". Per ClinicalTrias.gov, more information regarding the primary purpose is described here; this study is a pediatric taste test.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 157
Inclusion Criteria
- Female or male child age 4 through 8 years in good general health.
- Minimum weight of 16.3 kg (36 lb).
- Willing to comply with appropriate instructions provided to complete the study.
- Written informed consent from parent/legal guardian.
Exclusion Criteria
- Current medical condition, that in the opinion of the Investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, etc.).
- History of allergic reaction to cefdinir, azithromycin, prescription (e.g. penicillins or cephalosporins) and/or OTC medications, and/or food products.
- History of significant medical condition (e.g., GI disorders, hematological or bleeding disorders, renal or hepatic diseases).
- Use of any oral medication, vitamins or herbal supplements within 6 hours prior to tasting.
- Temperature > than 99.2°F. Participation in a clinical or marketing research study within the past 3 months.
- Sibling of another subject on the study, or living in the same household as another subject that has participated in a clinical or marketing research study within the past 3 months.
- Family member or close friend employed by an advertising agency, market research company, and/or a company that processes or manufacturers medical or health care products.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 cefdinir (Omnicef) - 2 azithromycin -
- Primary Outcome Measures
Name Time Method Taste and smell acceptance and preference 2 hours
- Secondary Outcome Measures
Name Time Method Adverse events assessment 72 hours with follow-up to a satisfactory conclusion Concomitant Medications 72 hours Vital signs 2 hours Any clinically abnormal observations 2 hours with follow-up to a satisfactory conclusion